Literature DB >> 32452650

Design and Synthesis of Fluorescent Methylphenidate Analogues for a FRET-Based Assay of Synapsin III Binding.

Andrea Casiraghi1,2, Francesca Longhena3, Valentina Straniero1, Gaia Faustini3, Amy H Newman2, Arianna Bellucci3, Ermanno Valoti1.   

Abstract

We previously described synapsin III (Syn III) as a synaptic phosphoprotein that controls dopamine release in cooperation with α-synuclein (aSyn). Moreover, we found that in Parkinson's disease (PD), Syn III also participates in aSyn aggregation and toxicity. Our recent observations point to threo-methylphenidate (MPH), a monoamine re-uptake inhibitor that efficiently counteracts the freezing-gait characteristic of advanced PD, as a ligand for Syn III. We have designed and synthesised two different fluorescently labelled MPH derivatives, one with Rhodamine Red (RHOD) and one with 5-carboxytetramethylrhodamine (TAMRA), to be used for assessing MPH binding to Syn III by FRET. TAMRA-MPH exhibited the ideal characteristics to be used as a FRET acceptor, as it was able to enter into the SK-N-SH cells and could interact specifically with human green fluorescent protein (GFP)-tagged Syn III but not with GFP alone. Moreover, the uptake of TAMRA-MPH and co-localization with Syn III was also observed in primary mesencephalic neurons. These findings support that MPH is a Syn III ligand and that TAMRA-conjugated drug molecules might be valuable tools to study drug-ligand interactions by FRET or to detect Syn III in cytological and histological samples.
© 2020 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  FRET; Parkinson's disease; Synapsin III binding; TAMRA; methylphenidate

Mesh:

Substances:

Year:  2020        PMID: 32452650      PMCID: PMC7486004          DOI: 10.1002/cmdc.202000128

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.540


  24 in total

1.  Expression of synapsin III in nerve terminals and neurogenic regions of the adult brain.

Authors:  Vincent A Pieribone; Barbara Porton; Beatrice Rendon; Jian Feng; Paul Greengard; Hung-Teh Kao
Journal:  J Comp Neurol       Date:  2002-12-09       Impact factor: 3.215

2.  Alpha-synuclein/synapsin III pathological interplay boosts the motor response to methylphenidate.

Authors:  Gaia Faustini; Francesca Longhena; Agostino Bruno; Federica Bono; Jessica Grigoletto; Luca La Via; Alessandro Barbon; Andrea Casiraghi; Valentina Straniero; Ermanno Valoti; Gabriele Costantino; Fabio Benfenati; Cristina Missale; Marina Pizzi; Maria Grazia Spillantini; Arianna Bellucci
Journal:  Neurobiol Dis       Date:  2020-02-04       Impact factor: 5.996

3.  Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease.

Authors:  D Devos; P Krystkowiak; F Clement; K Dujardin; O Cottencin; N Waucquier; K Ajebbar; B Thielemans; M Kroumova; A Duhamel; A Destée; R Bordet; L Defebvre
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-11-10       Impact factor: 10.154

4.  Low dose methylphenidate improves freezing in advanced Parkinson's disease during off-state.

Authors:  L Pollak; Y Dobronevsky; T Prohorov; S Bahunker; J M Rabey
Journal:  J Neural Transm Suppl       Date:  2007

Review 5.  Review: Parkinson's disease: from synaptic loss to connectome dysfunction.

Authors:  Arianna Bellucci; Nicola Biagio Mercuri; Annalena Venneri; Gaia Faustini; Francesca Longhena; Marina Pizzi; Cristina Missale; PierFranco Spano
Journal:  Neuropathol Appl Neurobiol       Date:  2016-02       Impact factor: 8.090

6.  Parkinson's disease-related protein, alpha-synuclein, in malignant melanoma.

Authors:  Yasuhiro Matsuo; Tetsu Kamitani
Journal:  PLoS One       Date:  2010-05-05       Impact factor: 3.240

Review 7.  Synaptic failure and α-synuclein.

Authors:  Laura Calo; Michal Wegrzynowicz; Jessica Santivañez-Perez; Maria Grazia Spillantini
Journal:  Mov Disord       Date:  2016-01-21       Impact factor: 10.338

Review 8.  Characterization and quantification of freezing of gait in Parkinson's disease: Can detection algorithms replace clinical expert opinion?

Authors:  A Delval; C Tard; M Rambour; L Defebvre; C Moreau
Journal:  Neurophysiol Clin       Date:  2015-11-05       Impact factor: 3.734

Review 9.  A Guide to Fluorescent Protein FRET Pairs.

Authors:  Bryce T Bajar; Emily S Wang; Shu Zhang; Michael Z Lin; Jun Chu
Journal:  Sensors (Basel)       Date:  2016-09-14       Impact factor: 3.576

10.  The End Is the Beginning: Parkinson's Disease in the Light of Brain Imaging.

Authors:  Arianna Bellucci; Angelo Antonini; Marina Pizzi; PierFranco Spano
Journal:  Front Aging Neurosci       Date:  2017-10-10       Impact factor: 5.750

View more
  3 in total

1.  Synapsin III gene silencing redeems alpha-synuclein transgenic mice from Parkinson's disease-like phenotype.

Authors:  Gaia Faustini; Francesca Longhena; Anna Masato; Valentina Bassareo; Roberto Frau; Therése Klingstedt; Hamid Shirani; Viviana Brembati; Edoardo Parrella; Marika Vezzoli; K Peter R Nilsson; Marina Pizzi; Maria Grazia Spillantini; Luigi Bubacco; Arianna Bellucci
Journal:  Mol Ther       Date:  2022-01-14       Impact factor: 12.910

2.  Methylphenidate Analogues as a New Class of Potential Disease-Modifying Agents for Parkinson's Disease: Evidence from Cell Models and Alpha-Synuclein Transgenic Mice.

Authors:  Andrea Casiraghi; Francesca Longhena; Gaia Faustini; Giovanni Ribaudo; Lorenzo Suigo; Gisela Andrea Camacho-Hernandez; Federica Bono; Viviana Brembati; Amy Hauck Newman; Alessandra Gianoncelli; Valentina Straniero; Arianna Bellucci; Ermanno Valoti
Journal:  Pharmaceutics       Date:  2022-07-30       Impact factor: 6.525

3.  Illuminating the norepinephrine transporter: fluorescent probes based on nisoxetine and talopram.

Authors:  Gisela Andrea Camacho-Hernandez; Andrea Casiraghi; Deborah Rudin; Dino Luethi; Therese C Ku; Daryl A Guthrie; Valentina Straniero; Ermanno Valoti; Gerhard J Schütz; Harald H Sitte; Amy Hauck Newman
Journal:  RSC Med Chem       Date:  2021-06-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.